{
    "clinical_study": {
        "@rank": "161323", 
        "arm_group": [
            {
                "arm_group_label": "Zegerid 20mg capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate"
            }, 
            {
                "arm_group_label": "Zegerid 20mg powder for oral suspension", 
                "arm_group_type": "Active Comparator", 
                "description": "Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)"
            }, 
            {
                "arm_group_label": "Losec 20mg capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "Losec 20mg capsule (20mg omeprazole)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder\n      and Losec 20mg capsules in healthy volunteers under fasting conditions."
        }, 
        "brief_title": "A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Acid Reflux", 
            "Gastro Oesophageal Reflux Disease"
        ], 
        "condition_browse": {
            "mesh_term": "Gastroesophageal Reflux"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult male or female volunteers aged 18 - 45 years.\n\n          -  Non-smokers from three months before receiving the first dose and for the duration of\n             the study, confirmed by negative urinary cotinine test at screening and check-in.\n\n          -  Body mass index (BMI) \u2265 18.0 and \u2264 27.9 kg/m2.\n\n          -  Able to voluntarily provide written informed consent to participate in the study.\n\n          -  Must understand the purposes and risks of the study and agree to follow the\n             restrictions and schedule of procedures as defined in the protocol.\n\n          -  Able and willing to have a nasogastric tube/probe inserted.\n\n          -  Females must be post-menopausal (for at least one year and confirmed by serum FSH at\n             screening), surgically sterile, practicing true sexual abstinence or using an\n             acceptable form of effective contraception throughout the study from the following\n             list: contraceptive implants, injectables, oral contraceptives, intrauterine system\n             (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method\n             (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository.\n\n          -  Hormonal and IUD methods of contraception must be established for a period of three\n             months prior to dosing and cannot be changed or altered during the study.\n\n          -  Females of childbearing potential must have a negative pregnancy test at screening\n             and check-in.\n\n          -  Must be willing to consent to have data entered into The Over Volunteering Prevention\n             System (TOPS).\n\n          -  The volunteer's primary care physician must confirm that there is nothing in their\n             medical history that would preclude their enrolment into this clinical study.\n\n        Exclusion Criteria:\n\n          -  Positive for HIV, hepatitis B or hepatitis C.\n\n          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,\n             or psychiatric disease as determined by the Investigator.\n\n          -  History of gastric or duodenal ulcer.\n\n          -  History of hiatus hernia.\n\n          -  Significant history of reflux symptoms on clinical judgement.\n\n          -  Diagnosis of conditions likely to result in a hypersecretory gastric acid state e.g.\n             Zollinger-Ellison Syndrome.\n\n          -  Positive serology test result for H. pylori at screening.\n\n          -  Clinically significant deviated nasal septum or other nasopharyngeal obstruction, or\n             inability to tolerate or site a nasogastric tube at screening.\n\n          -  Hypersensitivity or any other contraindication to Zegerid\u00ae or Losec\u00ae.\n\n          -  History or presence of any clinically significant drug allergy.\n\n          -  Female subjects who are pregnant or lactating.\n\n          -  Laboratory values at screening which are deemed to be clinically significant as\n             determined by the Investigator.\n\n          -  Any clinically relevant history of drug or alcohol abuse.\n\n          -  Volunteers who, in the opinion of the Investigator, are unsuitable for participation\n             in the study.\n\n          -  Participation in a clinical drug study during the 90 days preceding the initial dose\n             of study medication.\n\n          -  Any significant illness during the screening period preceding the initial dose of\n             study medication.\n\n          -  Donation of blood or blood products within 90 days prior to study drug\n             administration, or at any time during the study, except as required by this protocol.\n\n          -  Consumption of alcoholic beverages or xanthine-containing products within 24 hours\n             before confinement or during study confinement.\n\n          -  Consumption of cruciferous vegetables or chargrilled foods within 48 hours before\n             confinement or during study confinement.\n\n          -  Consumption of grapefruit or grapefruit juice from seven days before confinement and\n             until the end of the study.\n\n          -  Use of any prescription or over-the-counter medication (including vitamins, herbal\n             and mineral supplements) within 30 days before study drug  administration, or any\n             general anaesthetic during the three months before study drug administration, and\n             until the end of the study, with the exception of Investigator-approved hormonal\n             contraceptives, HRT and occasional paracetamol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710995", 
            "org_study_id": "ZEG-02/2010 (BE)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Zegerid 20mg capsule", 
                    "Zegerid 20mg powder for oral suspension"
                ], 
                "intervention_name": "Zegerid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Losec 20mg capsule", 
                "intervention_name": "Losec", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Omeprazole", 
                "Omeprazole, sodium bicarbonate drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 17, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Belfast", 
                    "country": "United Kingdom", 
                    "zip": "BT2 7BA"
                }, 
                "name": "Bio-Kinetic Europe Limited, 14 Great Victoria Street, Belfast BT2 7BA"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Three-Period, Single Dose, Open-Label, Crossover Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions", 
        "overall_official": {
            "affiliation": "Bio-Kinetic Europe Ltd", 
            "last_name": "Jerome Hanna, MB BCH MRCS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To assess the relative bioavailability of two immediate release formulations of omeprazole/sodium carbonate (Zegerid 20mg capsule and Zegerid 20mg powder for oral suspension)", 
                "measure": "Bioavailability - Area under Curve of pH at 2 hours", 
                "safety_issue": "No", 
                "time_frame": "2 hours"
            }, 
            {
                "description": "To assess the relative pharmacodynamic profiles of two immediate release formulations of omeprazole/sodium bicarbonate (Zegerid\u00ae 20mg capsule and Zegerid\u00ae 20mg powder for oral suspension).", 
                "measure": "Pharmacodynamics - Area under Curve of pH at 2 hours", 
                "safety_issue": "No", 
                "time_frame": "2 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710995"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the safety and tolerability of these three formulations after single dose oral administration. To include measurements of Cmax, tmax and t1/2", 
                "measure": "Safety and tolerability of study formulations using measurements of Cmax, tmax and t1/2", 
                "safety_issue": "No", 
                "time_frame": "pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose"
            }, 
            {
                "description": "To assess the relative bioavailability of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. AUC of pH and % of time for pH to raise above 4 (0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours)", 
                "measure": "Bioavailability - measurement of pH over time", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours"
            }, 
            {
                "description": "To assess the relative bioavailability of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg powder for oral suspension) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. AUC of pH and % of time for pH to raise above 4 (0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours)", 
                "measure": "Bioavailability - measurement of pH over time", 
                "safety_issue": "No", 
                "time_frame": "0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours"
            }, 
            {
                "description": "To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state.", 
                "measure": "Pharmacodynamic Measurements of Cmax, Tmax and t1/2", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose"
            }, 
            {
                "description": "To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg powder for oral suspension) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state", 
                "measure": "Pharmacodynamic measurements of Cmax, Tmax and t1/2", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose"
            }
        ], 
        "source": "Norgine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Norgine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}